AnDiConBio
About:
AnDiConBio develops innovative respiratory anti-infection drugs, focusing on pain and respiratory issues.
Website: http://www.andicon.cn
Top Investors: Cowin Capital, Simcere Pharma, Huajin Capital, Wenzhou Capital, Jinshajiang United Runpu Medical Fund
Description:
developer of respiratory anti-infection drugs, offering high-potential, low-risk products like new anti-influenza and oral anti-new coronavirus.
Total Funding Amount:
200M CNY
Headquarters Location:
Jiaxing, Zhejiang, China
Founded Date:
2018-01-01
Founders:
Number of Employees:
11-50
Last Funding Date:
2024-04-29
IPO Status:
Private
Industries:
© 2025 bioDAO.ai